Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GLSI

Greenwich LifeSciences

GLSI Lead: Phase 3 ★ Read the deep dive → 13 Biotech Distilled articles ↓ 13 filings & releases ↓ Cash $8.9M (Jun 30, 2026) ↓ 13 verdicts ↓
Oncology Peptide

Market cap $223M 14.7M shares (10-Q, Jul 24, 2026) × $15.17 close Nov 6, 2026

Most recent annual filing: 2026-06-01

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Insider lock-up corporate updateJan 31, 2027Insider lock-up corporate update, Jan 31, 2027, routine
  2. GLSI insider lock-up corporate updateJan 31, 2027GLSI insider lock-up corporate update, Jan 31, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Capital (as filed)

Cash
$8.9M cash, equivalents and restricted cash · Jun 30, 2026 (10-Q)
Operating cash flow
−$1.9M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$8.9M cash per the update of Aug 11, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (13)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (13 calls)

Every verdict Biotech Distilled has published on Greenwich LifeSciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-26 Watch Greenwich LifeSciences (GLSI): Scientific Due Diligence for GLSI-100 Science is intriguing but the Dilution Gap is terrifying; prudent to wait for the inevitable capital raise before entering.
  2. 2026-01-25 Hold Update: Greenwich LifeSciences (GLSI) - The Boring News That Actually Matters FDA approval of commercial GP2 vials de-risks manufacturing but solvency remains the elephant in the room; hold and accumulate on dips.
  3. 2026-01-30 Hold UPDATE: Greenwich Lifesciences (GLSI) - The ATM Just Printed $7 Million. Is the Cash Crunch Over? ATM raise of $7M doubles cash and reduces near-term insolvency risk, keeping the bull case intact while dilution remains real.
  4. 2026-02-28 Watch UPDATE: Greenwich LifeSciences (GLSI) - Mark Your Calendars. The Steering Committee Speaks. AACR abstract acceptance with full Steering Committee co-authorship keeps the narrative moving; mark calendars for March 17 and April 17 data drops.
  5. 2026-03-07 Watch UPDATE: Greenwich LifeSciences (GLSI) - Foot on the Gas. Screening Rate Jumps 33%. 33% jump in screening rate accelerates timeline to the 14-event interim analysis; clinical machinery is humming but biology still has to do its job.
  6. 2026-03-22 Hold UPDATE: Greenwich LifeSciences (GLSI) - The Data Firehose 83% recurrence reduction in open-label arm and statistically significant DTH immune response data reinforce the bullish binary; hold and accumulate on dips ahead of AACR.
  7. 2026-04-27 Hold UPDATE: Greenwich LifeSciences (GLSI) — The Protocol Pivot, the Patent Stretch, and a Late 10-K FDA protocol amendment and new patent to 2045 are mild bullish catalysts, but late 10-K, Nasdaq notice, and dual-auditor situation introduce a new governance yellow flag; size like a VC lottery ticket.
  8. 2026-06-02 Hold UPDATE: Greenwich LifeSciences (GLSI) — The 10-K Lands, ASCO Confirms the Mechanism 10-K filing closes Nasdaq overhang and two consecutive Steering Committee posters at p<0.001 across HLA types support the protocol amendment, but FY2025 audited burn is materially higher than January narrative.
  9. 2026-06-04 Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The 10-Q Decodes the 17% Drop Q1 10-Q reveals 129% R&D burn jump and material weakness in internal controls causing a 17% stock drop, but science is unchanged and the -17% dip makes the protocol amendment and mechanism confirmation less priced in; buy the dip sized as a VC lottery ticket.
  10. 2026-07-16 Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — Europe Falls in Line. The Interim Clock Just Sped Up. EMA approves combined-HLA protocol amendment, harmonizing all 170-180 global sites and unlocking European non-HLA-A*02 waitlist, mechanically compressing timeline to the 14-event interim analysis.
  11. 2026-07-20 Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The Interim Just Got Rewritten. Stock -26% in Two Sessions. Trial redesign doubles event trigger to 28, raises design HR to 0.55, and expands enrollment to 2,000 patients, materially delaying the interim but improving statistical power; stock round-trips to original entry at $14 and the VC lottery ticket framing reasserts itself.
  12. 2026-08-11 Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The Lock-Up Slides Again. September 30 Is Off the Board. Seventh sequential lock-up extension to January 31, 2027 removes September supply overhang and partnership language grows more specific, but science and governance flags are unchanged.
  13. 2026-08-12 Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The Burn Guide-Down Was Real. The Control Problems Weren't Fixed. Q2 burn of ~$1.94M validated management's guide and ATM activity collapsed, extending runway, but material weaknesses are re-disclosed verbatim and related-party reimbursements doubled; financial substrate firmed while governance remains yellow.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (13)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)